Gene Therapy Strategies for Tumor Antiangiogenesis

Kong, Hwai-Loong; Crystal, Ronald G.

doi:10.1093/jnci/90.4.261-a

Cited by 25 publications

(29 citation statements)

References 171 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[23][24][25] These proteins are good candidates for gene delivery because they are produced physiologically, indicating that they are probably not immunogenic, and they are effective extracellularly, which circumvents the need to transduce all tumor cells. In particular, sFLT-1 is considered a decoy receptor able to bind and inactivate VEGF function, thus limiting its trophic effect on endothelium.…”

Section: Introductionmentioning

confidence: 99%

Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer

et al. 2003

View full text Add to dashboard Cite

Treatments available to women with locally advanced breast cancer are unsatisfactory, since most patients succumb to metastatic spread. Therefore, there is a need to devise novel therapeutic combinations that effectively inhibit metastatization and to test them in animal models of breast cancer showing strong similarities with their human counterpart, including the ability to give rise to metastases. With these considerations in mind, tamoxifen (TAM), 4-hydrotamoxifen (4-HT) or liposome-complexed DNA constructs coding for antiangiogenic/anti-invasion proteins (angiostatin, TIMP-2, IFN-a 1 , sFLT-1) were individually administered to MMTVneu transgenic mice. Significant inhibition of primary tumor growth was obtained with TAM (40% inhibition, P¼0.049), angiostatin (85% inhibition, P¼0.001) and TIMP-2 (60% inhibition, P¼0.015). No lung metastasis was observed in any of these treated mice at 5 months, compared with a rate of 70% in control groups. These observations were the basis for designing a combined treatment with all these compounds. The association of angiostatin, TIMP-2 and TAM was greatly effective at the primary tumor level (90% inhibition, P¼0.01). Moreover, all the mice treated with this association were metastasis free at a time point (6 months) in which seven out of nine control mice were either dead from disseminated cancer or showed lung metastasis. This combined therapy could become an important component of anticancer therapy in humans.

show abstract

Section: Introductionmentioning

confidence: 99%

Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer

et al. 2003

View full text Add to dashboard Cite

show abstract

“…[9][10][11] Angiostatic therapy appears to require long-term administration of the inhibitor to ensure tumor growth suppression in vivo. 1 Long-term systemic delivery of recombinant molecules is expensive, time-consuming for the patient, and may be insufficient to obtain high local concentrations of the therapeutic molecule in the tumor mass. The delivery of the molecule through a gene therapy approach could be a solution, as it would lead to constantly high local levels of the anti-angiogenic protein.…”

Section: Introductionmentioning

confidence: 99%

Differential effects of angiostatin, endostatin and interferon-α1 gene transfer on in vivo growth of human breast cancer cells

et al. 2002

View full text Add to dashboard Cite

“…5 While viral vectors are commonly used for gene transfer into skeletal muscle, naked DNA is now receiving considerable attention for gene transfer into muscle tissue, owing to its safety, simplicity and reliability. 4,6,7,13 However, as the transfection efficiency of naked DNA by intra-muscular injection is relatively low, this method would not suffice for the treatment of systemic diseases. In our study, ultrasound microbubblesmediated gene transfer allowed us to reduce the amount of naked DNA from 500 to 25 mg/mouse, confirming recent reports, which state that ultrasound microbubblesmediated gene transfer improves transfection efficiency and facilitates local gene expression in various tissues, such as cardiac muscle, 9 skeletal muscle, 14 carotid artery 15 and the fetus.…”

Section: Cancer Gene Therapy By Adrenomedullin Antagonistmentioning

confidence: 99%

Suppression of tumor growth by intra-muscular transfer of naked DNA encoding adrenomedullin antagonist

et al. 2006

View full text Add to dashboard Cite

We have recently reported that the intra-tumoral injection of adrenomedullin (AM) antagonist (AMA; AM (22-52)) peptides significantly reduced the in vivo growth of a pancreatic cancer cell line in severely combined immunodeficient (SCID) mice. In the present study, we examined the effects of intra-tumoral and intra-muscular transfers of naked DNA encoding AMA on the in vivo growth of cancer cell lines. We demonstrate that these treatments induce the regression of a pancreatic cancer cell line and a breast cancer cell line inoculated in SCID mice. Furthermore, CD31-positive cells disappear completely from tumor tissues, following treatment, indicating that neo-vascularization is entirely inhibited. These results suggest that the intra-tumoral or intra-muscular transfer of naked DNA encoding AMA might be a promising alternative modality for treating human cancers.

show abstract

Gene Therapy Strategies for Tumor Antiangiogenesis

Cited by 25 publications

References 171 publications

Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer

Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer

Differential effects of angiostatin, endostatin and interferon-α1 gene transfer on in vivo growth of human breast cancer cells

Suppression of tumor growth by intra-muscular transfer of naked DNA encoding adrenomedullin antagonist

Contact Info

Product

Resources

About